When the patients were stratified based upon assessment of their pre-operative risk score (a proprietary package similar to Parsonnet’s), only two interventions revealed significant improvement in outcomes.
Low risk patients comprise more than 70% of the patient population and in this group Total Leukocyte Control effected a 20% reduction in length of stay in the hospital and a $6,000 reduction in charges per patient.
For the much smaller high risk patient population, Aprotinin provided significant reduction in both indices measured.
These data suggest hat the greatest good provided to the greatest number of patients accrued with TLC program of treatment.
The next figure illustrates just how TLC can be implemented throughout the operative procedure.